Pharmesis International (SGX:BFK) Momentum Rank : 0 (As of May. 29, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International Momentum Rank?

Pharmesis International has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Pharmesis International Momentum Rank Related Terms

Thank you for viewing the detailed overview of Pharmesis International's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmesis International (SGX:BFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Kallang Sector, No. 03-02, Singapore, SGP, 349279

Website

https://www.pharmesis.com

Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its geographical segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.

Pharmesis International (SGX:BFK) Headlines

From GuruFocus

Certain BlackRock Municipal Closed-End Funds Announce Variable Rate Muni Term Preferred Shares Actions

By Business Wire • 11-02-2023